Sporadic Creutzfeldt-Jakob Disease

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Second Edition

Volumn , Issue , 2011, Pages 322-335

  Budka, Herbert ^a   Head, Mark W ^b   Ironside, James W ^b   Gambetti, Pierluigi ^c   Parchi, Piero ^d   Tagliavini, Fabrizio ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Creutzfeldt Jakob disease; Genetic polymorphism; Immunoblotting; Immunohistochemistry; Neuropathology; Prion protein; Prion protein gene; Transmissible spongiform encephalopathy

Indexed keywords

EID: 84860901441     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341256.ch32     Document Type: Chapter

References (77)

1. Creutzfeldt H. Über eine eigenartige herdförmige Erkrankung des Zentralnervensystems. Z ges Neurol Psychiat 1920; 57: 1-18.
2. Jakob A. Über eigenartige Erkrankungen des Zentralnervensystems mit bemerkenswerten anatomischen Befunde (Spastische Pseudosklerose-Encephalomyelopathie mit disseminierten Degenerationsherden). Z ges Neurol Psychiat 1921; 64: 147-228.
3. Gelpi E, Heinzl H, Höftberger R, et al. Creutzfeldt-Jakob disease in Austria: an autopsy-controlled study. Neuroepidemiology 2008; 30: 215-221.
4. Comoy EE, Casalone C, Lescoutra-Etchegaray N, et al. Atypical BSE (BASE) transmitted from asymptomatic aging cattle to a primate. PLoS One 2008; 3: e3017.
5. Béringue V, Herzog L, Reine F, et al. Transmission of atypical bovine prions to mice transgenic for human prion protein. Emerg Infect Dis 2008; 14: 1898-1901.
6. Kong Q, Zheng M, Casalone C, et al. Evaluation of the human transmission risk of an atypical bovine spongiform encephalopathy prion strain. J Virol 2008; 82: 3697-3701.
7. Wientjens D, Davanipour Z, Hofman A, et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996; 46: 1287-1291.
8. Ward HJ, Everington D, Cousens SN, et al. Risk factors for sporadic Creutzfeldt-Jakob disease. Ann Neurol 2008; 63: 347-354.
9. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991; 352: 340-342.
10. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to iatrogenic Creutzfeldt-Jakob disease. Lancet 1991; 337: 1441-1442.
11. Pocchiari M, Poleggi A, Principe S, Graziano S, Cardone F. Genomic and post-genomic analyses of human prion diseases. Genome Med 2009; 1: 63.
12. Brown P, Gibbs C, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institute of Health series of 300 cases of experimentally transmitted disease. Ann Neurol 1994; 35: 513-529.
13. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 1999; 46: 224-233.
14. Pocchiari M, Puopolo M, Croes E, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain 2004; 127: 2348-2359.
15. Poser S, Mollenhauer B, Kraubeta A, et al. How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain 1999; 122: 2345-2351.
16. Zerr I, Kallenberg K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 2009; 132: 2659-2668.
17. Meissner B, Kallenberg K, Sanchez-Juan P, et al. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease. Neurology 2009; 72: 1994-2001.
18. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000; 55: 811-815.
19. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002; 58: 192-197.
20. Sanchez-Juan P, Green A, Ladogana A, et al. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2006; 67: 637-643.
21. Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol 1995; 5: 459-466.
22. Zeidler M, Gibbs CJ, Meslin F. WHO Manual for Strengthening Diagnosis and Surveillance of Creutzfeldt-Jakob Disease. Geneva: WHO, 1998.
23. Richardson EP Jr, Masters CL. The nosology of Creutzfeldt-Jakob disease and conditions related to the accumulation of PrPCJD in the nervous system. Brain Pathol 1995; 5: 33-41.
24. Kretzschmar HA, Ironside JW, DeArmond SJ, Tateishi J. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch Neurol 1996; 53: 913-920.
25. Park TS, Kleinman GM, Richardson EP. Creutzfeldt-Jakob disease with extensive degeneration of white matter. Acta Neuropathol (Berl) 1980; 52: 239-242.
26. Mizutani T, Okumura A, Oda M, Shiraki H. Panencephalopathic type of Creutzfeldt-Jakob disease: primary involvement of the cerebral white matter. J Neurol Neurosurg Psychiatry 1981; 44: 103-115.
27. Jansen C, Head MW, Rozemuller AJ, Ironside JW. Panencephalopathic Creutzfeldt-Jakob disease in the Netherlands and the UK: clinical and pathological characteristics of nine patients. Neuropathol Appl Neurobiol 2009; 35: 272-282.
28. Gray F, Chretien F, Adle-Biassette H, et al. Neuronal apoptosis in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 1999; 58: 321-328.
29. Guentchev M, Hainfellner JA, Trabattoni GR, Budka H. Distribution of parvalbumin-immunoreactive neurons in brain correlates with hippocampal and temporal cortical pathology in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 1997; 56: 1119-1124.
30. Salazar AM, Masters CL, Gajdusek DC, Gibbs CJ Jr. Syndromes of amyotrophic lateral sclerosis and dementia: relation to transmissible Creutzfeldt-Jakob disease. Ann Neurol 1983; 14: 17-26.
31. Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H. Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 1998; 96: 116-122.
32. Liberski PP, Budka H. Neuroaxonal pathology in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 1999; 97: 329-334.
33. Taraboulos A, Jendroska K, Serban D, Yang SL, DeArmond SJ, Prusiner SB. Regional mapping of prion proteins in brain. Proc Natl Acad Sci USA 1992; 89: 7620-7624.
34. Schulz-Schaeffer WJ, Tschoke S, Kranefuss N, et al. The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am J Pathol 2000; 156: 51-56.
35. Giaccone G, Canciani B, Puoti G, et al. Creutzfeldt-Jakob disease: Carnoy's fixative improves the immunohistochemistry of the proteinase K-resistant prion protein. Brain Pathol 2000; 10: 31-37.
36. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183-189.
37. Hainfellner JA, Budka H. Disease associated prion protein may deposit in the peripheral nervous system in human transmissible spongiform encephalopathies. Acta Neuropathol (Berl) 1999; 98: 458-460.
38. Bell JE, Gentleman SM, Ironside JW, et al. Prion protein immunocytochemistry-UK five centre consensus report. Neuropathol Appl Neurobiol 1997; 23: 26-35.
39. Van Everbroeck B, Pals P, Martin JJ, Cras P. Antigen retrieval in prion protein immunohistochemistry. J Histochem Cytochem 1999; 47: 1465-1470.
40. Kovács GG, Head M, Hegyi I, et al. Immunohistochemistry for the prion protein: comparison of different monoclonal antibodies in human prion disease subtypes. Brain Pathol 2002; 12: 1-11.
41. Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 1996; 39 (6): 767-778.
42. Kitamoto T, Shin RW, Doh-ura K, et al. Abnormal isoform of prion protein accumulates in the synaptic structures of the central nervous system in patients with Creutzfeldt-Jakob disease. Am J Pathol 1992; 140: 1285-1294.
43. Kovács GG, Preusser M, Strohschneider M, Budka H. Subcellular localization of disease associated prion protein in the human brain. Am J Pathol 2005; 166: 287-294.
44. Will R, Ironside J, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-925.
45. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 349: 1812-1820.
46. Peden AH, Ritchie DL, Head MW, Ironside JW. Detection and localization of PrPSc in the skeletal muscle of patients with variant, iatrogenic, and sporadic Creutzfeldt-Jakob disease. Am J Pathol 2006; 168: 927-935.
47. Peden AH, Ritchie DL, Uddin HP, et al. Abnormal prion protein in the pituitary in sporadic and variant Creutzfeldt-Jakob disease. J Gen Virol 2007; 88: 1068-1072.
48. Liberski PP, Yanagihara R, Wells GA, Gibbs CJ Jr, Gajdusek DC. Comparative ultrastructural neuropathology of naturally occurring bovine spongiform encephalopathy and experimentally induced scrapie and Creutzfeldt-Jakob disease. J Comp Pathol 1992; 106: 361-381.
49. Liberski PP, Budka H, Sluga E, Barcikowska M, Kwiecinski H. Tubulovesicular structures in Creutzfeldt-Jakob disease. Acta Neuropathol (Berl) 1992; 84: 238-243.
50. Parchi P, Capellari S, Chen SG, et al. Typing prion isoforms. Nature 1997; 386: 232-234.
51. Parchi P, Zou W, Wang W, et al. Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci USA 2000; 97: 10168-10172.
52. Parchi P, Notari S, Weber P, et al. Inter-laboratory assessment of PrP Sc typing in Creutzfeldt-Jakob disease: a Western blot study within the NeuroPrion Consortium. Brain Pathol 2009; 19: 384-391.
53. Hill AF, Joiner S, Wadsworth JD, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain 2003; 126: 1333-1346.
54. Pan T, Colucci M, Wong BS, et al. Novel differences between two human prion strains revealed by two-dimensional gel electrophoresis. J Biol Chem 2001; 276: 37284-37288.
55. Notari S, Strammiello R, Capellari S, et al. Characterization of truncated forms of abnormal prion protein in Creutzfeldt-Jakob disease. J Biol Chem 2008; 283: 30557-30565.
56. Parchi P, Stammiello R, Notari S, et al. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotypes and co-occurrence of PrP Sc types: an updated classification. Acta Neuropathol 2009; 118: 659-671.
57. Kovács GG, Gelpi E, Ströbel T, et al. Involvement of the endosomal-lysosomal system correlates with regional pathology in Creutzfeldt-Jakob disease. J Neuropathol Exp Neurol 2007; 66: 628-636.
58. Kovacs GG, Budka H. Distribution of apoptosis-related proteins in sporadic Creutzfeldt-Jakob disease. Brain Res 2010; 1323: 192-199.
59. Puoti G, Giaccone G, Mangieri M, et al. Sporadic Creutzfeldt-Jakob disease: the extent of microglia activation is dependent on the biochemical type of PrPSc. J. Neuropathol Exp Neurol 2005; 64: 902-909.
60. Puoti G, Giaccone G, Rossi G, Canciani B, Bugiani O, Tagliavini F. Sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrP sc in the same brain. Neurology 1999; 53: 2173-2176.
61. Cali I, Castellani R, Alshekhlee A, et al. Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 2009; 132: 2643-2658.
62. Head MW, Ironside JW. Sporadic Creutzfeldt-Jakob disease: discrete subtypes or a spectrum of disease? Brain 2009; 132: 2627-2629.
63. Polymenidou M, Stoeck K, Glatzel M, Vey M, Bellon A, Aguzzi A. Coexistence of multiple PrPSc types in individuals with Creutzfeldt-Jakob disease. Lancet Neurol 2009; 4: 805-814.
64. Yull HM, Ironside JW, Head MW. Further characterisation of the prion protein molecular types detectable in the NIBSC Creutzfeldt-Jakob disease brain reference materials. Biologicals 2009; 37: 210-215.
65. Notari S, Capellari S, Langeveld J, et al. A refined method for typing reveals that co-occurrence of PrP Sc types in Creutzfeldt-Jakob disease is not the rule. Lab Invest 2007; 87: 1103-1112.
66. Prusiner SB. Prions. Proc Natl Acad Sci USA 2008; 95: 13363-13383.
67. Kovács GG, Budka H. Prion diseases: from protein to cell pathology. Am J Pathol 2008; 172: 555-565.
68. Forloni GL, Angeretti N, Chiesa R, et al. Neurotoxicity of a prion protein fragment. Nature 1993; 362: 543-546.
69. Tagliavini F, Forloni G, d'Ursi P, Bugiani O, Salmona M. Studies on peptide fragments of prion proteins. Adv Protein Chem 2001; 57: 171-202.
70. Saborio GP, Permanne B, Soto C. Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature 2001; 411: 810-813.
71. Castilla J, Morales R, Saa P, Barria M, Gambetti P, Soto C. Cell-free propagation of prion strains. EMBO J 2008; 27: 2557-2566.
72. Jones M, Peden AH, Wight D, et al. Effects of human PrP Sc type and PRNP genotype in an in-vitro conversion assay. NeuroReport 2008; 19: 1783-1786.
73. Rossi G, Salmona M, Forloni G, Bugiani O, Tagliavini F. Therapeutic approaches to prion diseases. Clin Lab Med 2003; 23: 187-208.
74. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8: 334-344.
75. Haïk S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004; 63: 2413-2415.
76. Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001; 98: 9836-9841.
77. Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and prion infectivity. Infect Disord Drug Targets 2009; 9: 23-30.